CYTL1

Across TCGA pan-cancer cohorts, CYTL1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CYTL1 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CYTL1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CYTL1 expression acts as an unfavorable survival marker.

GBM, HNSC, and LSCC are the cancer types where CYTL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.443	0.809	.038	6	view →
HNSC	OS	Median	IV	0.644	1.000	.034	3	view →
LSCC	DFS	Quartile	All	0.442	0.930	.026	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CYTL1–GBM (DFS)

Open the GBM breakdown →